News

Bal Pharma announced that the Board of Directors of the Company at its meeting held on 27 May 2026, inter alia, have recommended the final dividend of Rs 1.2 per equity Share (i.e. 12%) , subject to the approval of the shareholders.

Net profit of Bal Pharma declined 33.89% to Rs 3.59 crore in the quarter ended March 2026 as against Rs 5.43 crore during the previous quarter ended March 2025. Sales rose 2.69% to Rs 84.08 crore in the quarter ended March 2026 as against Rs 81.88 crore during the previous quarter ended March 2025.For the full year,net profit declined 13.02% to Rs 6.28 crore in the year ended March 2026 as against Rs 7.22 crore during the previous year ended March 2025. Sales rose 2.83% to Rs 311.66 crore in the year ended March 2026 as against Rs 303.08 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales84.0881.88 3 311.66303.08 3 OPM %12.579.33 -10.249.75 - PBDT6.284.77 32 17.0114.91 14 PBT3.222.59 24 5.935.14 15 NP3.595.43 -34 6.287.22 -13 Powered by Capital Market - Live News

Bal Pharma will hold a meeting of the Board of Directors of the Company on 27 May 2026.

Net profit of Bal Pharma rose 270.83% to Rs 1.78 crore in the quarter ended December 2025 as against Rs 0.48 crore during the previous quarter ended December 2024. Sales rose 19.88% to Rs 87.69 crore in the quarter ended December 2025 as against Rs 73.15 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales87.6973.15 20 OPM %10.8810.59 - PBDT5.023.25 54 PBT1.790.57 214 NP1.780.48 271 Powered by Capital Market - Live News

Bal Pharma will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live News